ESSA Pharma in Clinical Collaboration Agreement With Bayer
28 Abril 2021 - 7:16AM
Noticias Dow Jones
By Michael Dabaie
ESSA Pharma Inc. said Wednesday it is in a clinical trial
collaboration and supply agreement with Bayer.
ESSA, a clinical-stage pharmaceutical company, said the
agreement is to evaluate its lead product candidate, EPI-7386, in
combination with Bayer's darolutamide in patients with metastatic
castration-resistant prostate cancer.
Under the agreement, Bayer may sponsor and conduct a Phase 1/2
study. ESSA said it will supply EPI-7386 for the trial and will
retain all rights to EPI-7386. The clinical study is expected to
start in 2021.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 28, 2021 08:01 ET (12:01 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Bayer (TG:BAYN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024